本帖最后由 maicon08 于 2023-4-28 15:12 编辑 : F# _! N6 n& W( h
. ~9 z! c+ U; V, ?5 V一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。9 T* j% k7 j% |5 N
9 C7 w% J+ t$ Ehttps://www.163.com/dy/article/I3BTTPRD053438SI.html; k' U0 g' ?7 H! }, [5 h
; R# T X; x3 q: I! |! V9 M! [3 w& C* `7 U$ a2 ^ o
在研疗法-免疫治疗
2 _% V: M# r# T( U& J! fDevelopmental Therapeutics—Immunotherapy h0 w$ Z# l9 i5 [( T6 v, z3 p3 F
2 |6 |) d; l' U( a2 Z& }7 D摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心 0 x4 U% y0 o% T- m; c6 o
在研疗法-分子靶向药物和肿瘤生物学
4 q2 }( T1 K; q; _& D4 } Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology : r4 p+ @* I. j4 X! a0 V( O! M0 B. }
摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心
# y( G+ G( [4 l K) a
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院 : A# G3 I/ {8 E% B k6 v- Y
胃肠道肿瘤-结直肠癌和肛门癌
0 X& U( V: d H# B1 R5 ] Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院 d# f7 A( b" g7 R
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary ) l: |- e% F' N! g4 p/ s
摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心 / ?; | V- T/ B! ~3 N# H. D
妇科肿瘤 Gynecologic Cancer
8 Z f, G' P2 {) O" ~摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院
0 q4 B; U$ Q0 @
头颈肿瘤2 p1 ~- F) M8 `# ]* J Q* \8 Q! }
Head and Neck Cancer
1 k x" O* p5 t; U7 v$ `+ M5 Y摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心 / A$ t) p% @! F
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心
2 |! b* v" _ N
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心 + x9 Y7 Q+ z( X( p7 p
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia 0 G C4 q* l) H: z* P O
摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心 " @: ?. w2 E, P, f
血液系统恶性肿瘤-浆细胞疾病3 J" C1 @) g: @7 N2 C- I" {
Hematologic Malignancies—Plasma Cell Dyscrasia
! g V2 U9 U* \摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院 . ?( T. s4 p/ U3 B" d0 m5 E' \
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤" S% N& _& Y5 w) x
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers , ^ y- r' Q0 K1 E) u v
摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院
( t* k, `. h& V% \2 M' f" Z
肺癌-转移性非小细胞肺癌2 Z9 e6 m/ }% Z6 I
Lung Cancer—Non-Small Cell Metastatic
; w7 s7 L: O+ Z$ `+ D1 k摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院
7 x+ r5 {' {0 V, ~
& V7 X5 G: x8 ^* ^1 s) f摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院
+ P, p) Q1 D8 E
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院
2 H6 h, d. {) R7 j9 N- c t+ o0 o
黑色素瘤/皮肤癌
) n. @6 `4 t, k% v8 N8 A Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院
" e& ~$ I7 D' }% ^
快速摘要报告
& R# b) G. F1 o2 u Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心
. W) z8 |' W) p- g, q; u7 k2 J
临床科学研讨会& A& R" I+ a* q6 h1 J- o& y# j* d- A
Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院 : h! u& `& b0 b8 T) q: m
5 ]9 `9 k/ z) i; @
| 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
